Purpose:
To evaluate the consecutive treatment results regarding pterygium recurrence and the efficacy of exclusive strontium-/ yttrium-90 β-irradiation for primary and recurrent pterygia and to analyze the functional outcome.
Patients and Methods:
Between October 1974 and December 2005, 58 primary and 21 recurrent pterygia were exclusively treated with strontium-/yttrium-90 β-irradiation with doses ranging from 3,600 to 5,500 cGy. The follow-up time was 46.6 ± 26.7 months, with a median of 46.5 months.
Results:
The treatment led to a size reduction in all pterygia (p < 0.0001). Neither recurrences nor side effects were observed during therapy and follow-up in this study. Best-corrected visual acuity increased (p = 0.0064). Corneal astigmatism was reduced in recurrent pterygia (p = 0.009).
Conclusion:
Exclusive strontium-/yttrium-90 β-irradiation of pterygia is a very efficient and well-tolerated treatment, with remarkable aesthetic and rehabilitative results in comparison to conventional treatments, especially for recurrent lesions which have undergone prior surgical excision.
Ziel:
Evaluation der Behandlungsergebnisse in Bezug auf Rezidivrate, Effizienz und Funktion der ausschließlichen Strontium-/ Yttrium-90-β-Bestrahlung von primären und rezidierenden Pterygien. Analyse des kornealen und des refraktiven Astigmatismus im Vergleich zu den postoperativen Ergebnissen konventioneller Behandlungsmethoden.
Patienten und Methodik:
Zwischen Oktober 1974 und Dezember 2005 wurden 58 primäre und 21 rezidivierende Pterygien mit ausschließlicher Strontium-/Yttrium-90-β-Bestrahlung mit Dosen von 3 600–5 500 cGy behandelt. Die mittlere Nachbeobachtungszeit betrug 46,6 ± 26,7 Monate, median 46,5 Monate.
Ergebnisse:
Die Behandlung führte bei allen Pterygien zu einer Größenabnahme (p < 0,0001). Es wurden keine Rezidive und keine unerwünschten Nebenwirkungen beobachtet. Die bestkorrigierte Sehschärfe stieg signifikant an (p = 0,0064), der korneale Astigmatismus verkleinerte sich signifikant bei den rezidivierenden Pterygien (p = 0,009).
Schlussfolgerung:
Die ausschließliche Strontium-/Yttrium-90-β-Bestrahlung des Pterygiums ist eine sehr effiziente und gut tolerierte Behandlungsmethode mit einem bemerkenswerten ästhetischen und rehabilitativen Resultat in Vergleich zu den konventionellen Behandlungskonzepten, vor allem bei rezidivierenden Pterygien nach primärer operativer Exzision.
Similar content being viewed by others
References
Alaniz-Camino F. The use of postoperative beta irradiation in the treatment of pterygia. Ophthalmic Surg 1982;13:1022–1025.
Alpins N. Astigmatism analysis by the Alpins method. J Cataract Refract Surg 2001;27:31–49.
Anduze AL, Merritt JC. Pterygium: clinical classification and management in Virgin Islands. Ann Ophthalmol 1985;17:92–95.
Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007;18:308–313.
Avisar R, Loya N, Yassur Y, et al. Pterygium induced corneal astigmatism. Isr Med Assoc J 2000;2:14–15.
Ayukawa F, Shibuya H, Yoshimura R, et al. Curative brachytherapy for recurrent/residual tongue cancer. Strahlenther Onkol 2007;183:133–137.
Bahar I, Loya N, Weinberger D, et al. Effect of pterygium surgery on corneal topography: a prospective study. Cornea 2004;23:113–117.
Beyer DC. Pterygia: single fraction postoperative beta irradiation. Radiology 1991;178:569–571.
Bischof M, Karagiozidis M, Krempien R, et al. Radiotherapy for orbital lymphoma. Outcome and late effects. Strahlenther Onkol 2007;183:17–22.
Brenner DJ, Merriam GR. Postoperative irradiation for pterygium: guidelines for optimal treatment. Int J Radiat Oncol Biol Phys 1994;30:721–725.
Cameron ME. Histology of pterygium: an electron microscopy study. B J Ophthalmol 1983;67:604–608.
Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: A hypothesis. Br J Ophthalmol 1993;77:734–739.
Coroneo MT, Girolamo ND, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999;10:282–288.
Deitch RD, Wilson FM II. Management of pterygia. Principles and practice of ophthalmic plastic and reconstructive surgery. Bosniak S 1996;6:208–220.
Dunn JP, Seamone CD, Ostler HB, et al. Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy. Am J Ophthalmol 1991;112:343–344.
Dushku N, Molykutty KJ, Schultz GS, et al. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol 2001;119:695–706.
Errais K, Bouden J, Mili-Boussen I, et al. Effect of pterygium surgery on corneal topography. Eur J Ophthalmol 2008;18:177–181.
Fujitani A, Hayasaka S, Shibuya Y, et al. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. Ophthalmologica 1993;207:162–164.
Hayasaka S, Noda S, Yamamoto Y, et al. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1988;106:715–718.
Heyd R, Seegenschmiedt MH, Strassmann G, et al., German Cooperative Group on Radiotherapy for Benign Diseases (GCG). Radiotherapy for Graves’ orbitopathy: results of a national survey. Strahlenther Onkol 2003;179:372–376.
Hilgers JH. Strontium-90, beta irradiation, cataractogenicity and pterygium recurrence. Arch Ophthalmol 1976;81:891.
Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003;48:145–180.
Hirst LW. Prospective study of primary pterygium surgery using pterygium extended removal followed by extended conjunctival transplantation. Ophthalmology 2008;115:1663–1672.
Kampitak K. The effect of pterygium on corneal astigmatism. J Med Assoc Thai 2003;86:16–23.
Kria L, Ohira A, Ameniya T. Immunohistochemical localization of basic fibroblast growth factor, platelet delivered growth factor, transforming growth factor-β, and tumor necrosis factor-α in pterygia. Acta Histochem 1996;98:195–201.
Leccisotti A. Corneal topographic changes in a case of limbal conjunctival carcinoma. Cornea 2005;24:1021–1023.
Meineke V, Uebler C, Kohn FM, et al. Radiotherapy in benign diseases: Morbus Peyronie. Strahlenther Onkol 2003;179:181–186.
Mohammad-Salih P, Sharif A. Analysis of pterygium size and induced corneal astigmatism. Cornea 2008;27:434–438.
Morlet N, Minassian D, Dart J. Astigmatism and the analysis of its surgical correction. Br J Ophthalmol 2001;85:1127–1138.
Nowell JF. Management of pterygia 20 years later. South Med J 1986;79:1382–1384.
Oner FH, Kaderli B, Durak I, et al. Analysis of the pterygium size inducing marked refractive astigmatism. Eur J Ophthalmol 2000;10:212–214.
Pajic B, Pallas A, Aebersold D, et al. Prospective study on exclusive, nonsurgical strontium-/yttrium-90 irradiation of pterygia. Strahlenther Onkol 2004;180:510–516.
Panda A, Das GK, Tuli SW, et al. Randomized trial of intraoperative mitomycin-C in surgery for pterygium. Am J Ophthalmol 1998;125:59–63.
Paryani SB, Scott WP, Wells JW. Management of pterygium with surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1994;28:101–103.
Pavilack MA, Halpern BL. Corneal topographic changes induced by pterygia. J Refract Surg 1995;11:92–95.
Rödel F, Hofmann D, Auer J, et al. The anti-inflammatory effect of low-dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion. Strahlenther Onkol 2008;184:41–47.
Rödel F, Kamprad F, Sauer R, et al. Functional and molecular aspects of anti-inflammatory effects of low dose radiotherapy. Strahlenther Onkol 2002;178:1–9.
Rodriguez JA, Ferrari C, Hernández GA. Intraoperative application of topical mitomycin C 0.05% for pterygium surgery. Bol Asoc Med P R 2004;96:100–102.
Rubinfeld RS, Pfister RR, Stein RM. Serious complications of topical mitomycin C after pterygium surgery. Ophthalmology 1992;99:1647–1654.
Schäfer C, Koller C. Ethical and legal reasons why radiation treatment should be preapproved by informed consent. Strahlenther Onkol 2008;184:429–430.
Seitz B, Gütay A, Küchle M, et al. Impact of pterygium size on corneal topography and visual acuity. A prospective clinical cross sectional study. Klin Monatsbl Augenheilkd 2001;218:609–615.
Soriano JM, Janknecht P, Witschel H. Einfluß der Pterygiumoperation auf den präoperativen Astigmatismus. Ophthalmol 1993;90:688–690.
Tarr KH, Constable IJ. Late complications in pterygium treatment. Br J Ophthalmol 1980;64:496–505.
Taylor HR. Etiology of climatic droplet keratopathy and pterygium. Br J Ophthalmol 1980;64:154–163.
Tetsushi N, Watanabe I, Murakami A, et al. Expression of stem cell factor in pterygia. Jpn J Ophthalmol 2000;44:193–197.
Tomidokoro A, Oshika T, Amaro S, et al. Quantitative analysis of regular and irregular astigmatism induced by pterygium. Cornea 1999;18:412–415.
Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol 2006;182:431–436.
Van den Brenk HA. Results of prophylactic postoperative radiation in 1300 cases of pterygium. AJR 1968;103:723–733.
Viani GA, Stefano EJ, De Fendi LI, et al. Long-term results and prognostic factors of fractionated strontium-90 eye applicator for pterygium. Int J Radiat Oncol Biol Phys 2008;72:1174–1179.
Willner J, Flentje M, Lieb W. Soft X-ray therapy of recurrent pterygium — an alternative to 90-Sr eye applicators. Strahlenther Onkol 2001;177:404–409.
Wu HK. Astigmatism and LASIK. Curr Opin Ophthalmol 2002;13:250–255.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vastardis, I., Pajic, B., Greiner, R.H. et al. Prospective Study of Exclusive Strontium-/Yttrium-90 β-Irradiation of Primary and Recurrent Pterygia with No Prior Surgical Excision. Strahlenther Onkol 185, 808–814 (2009). https://doi.org/10.1007/s00066-009-2000-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-009-2000-1